Xenon Fell 30.7% After Pausing Two Depression Trials as Electra Closed 11.7% Below Its IPO Price and Grail’s Panel Neared With No Briefing Documents (September 21, 2026)

Last updated: September 21, 2026

Xenon Pharmaceuticals fell 30.7% Friday after pausing enrollment in two Phase 3 depression trials over neuropsychiatric adverse events, disclosed in the same release as its first NDA filing. Electra closed 11.7% below its $15.00 IPO price, and Grail’s Tuesday panel still has no briefing documents posted.

This report covers the Friday September 18 session and a weekend sweep through Sunday evening September 20, with verified figures from company releases, regulator pages, and exchange closes.

What did Xenon announce, and why did the stock fall 30.7%?

Xenon submitted its first NDA, for azetukalner in focal seizures, and in the same September 17 release paused new enrollment in its Phase 3 depression programs after an analysis of neuropsychiatric adverse events. The filing was the milestone; the market priced the pause.

The release crossed at 4:01 pm ET Thursday, one minute after the close, making Friday the first reaction session. XENE closed at $39.75, down 30.7% from Thursday’s $57.35, on 17.9 million shares against 1.8 million the day before. The decline is our arithmetic from the two exchange closes.

The paused studies are X-NOVA2, the Phase 3 major depressive disorder trial that had enrolled roughly 360 of a planned 450 patients, and X-CEED in bipolar depression. Xenon said the events had “not previously been seen in the Phase 2 X-NOVA clinical study in MDD” but called their rate and severity “consistent with the known safety and tolerability profile of azetukalner.” Patients already enrolled remain on drug, and the epilepsy studies X-TOLE3 and X-ACKT continue unaffected. Trade press reporting on the company’s call described the events as including psychosis, confusion, aphasia and ataxia, with one psychosis case each in the X-TOLE and X-TOLE2 epilepsy trials, per BioSpace. Chief medical officer Chris Kenney said the company is evaluating whether modifying the dose regimen could improve tolerability in depression.

The NDA itself rests on X-TOLE and X-TOLE2, where all four studied doses produced statistically significant seizure frequency reductions, with more than 1,500 patient years of safety data across the epilepsy program. BioSpace reported an anticipated FDA decision in September 2027. X-NOVA2 topline data are now expected in the first quarter of 2027, earlier than the prior first half guidance, because enrollment will close near 360 patients rather than 450. William Blair called the selloff overblown, noting blockbuster antidepressants carry psychosis at similar labeled rates; Jefferies has estimated azetukalner’s epilepsy opportunity above $2 billion. Both are analyst views, not company figures.

Xenon’s azetukalner program after the September 17 update

How much does Ultragenyx’s Fayuvi cost, and how did the market react?

Fayuvi’s US wholesale acquisition cost is $3.95 million per patient, stated by an Ultragenyx executive on the approval call and reported by Reuters, Endpoints, and BioSpace citing a Jefferies note. No pricing document has been published. RARE closed Friday essentially flat at $14.51.

That figure makes the Sanfilippo syndrome type A gene therapy the second most expensive gene therapy launched, behind Orchard’s Lenmeldy at $4.25 million, per BioSpace. The flat first reaction session is the notable part: RARE ran 12.6% Thursday before the evening release existed publicly, then added just a penny Friday once the approval, the price, and the launch details were all on the record. The disclosure was complete, and the tape had nothing left to price. The FDA also issued its own press announcement for the approval, a step its newsroom index skipped for Scholar Rock’s Isembyld earlier this month. Scholar Rock, by contrast, has still published no pricing document eight days after its approval; SRRK fell 4.8% Friday, its fifth straight post approval decline, following a Barclays downgrade as reported by market wires.

What happened in Electra’s first trading session?

Electra Therapeutics closed its first session at $13.25, 11.7% below the $15.00 offer price, after opening at the offer and touching $15.50. The company priced an upsized 23,333,334 share IPO Thursday night for gross proceeds of approximately $350.0 million.

The pricing release, carried September 17 at 8:30 pm ET, settles the raise at $350.0 million with a greenshoe of up to 3,500,000 additional shares, roughly $52.5 million more at the offer price. The deal closes Monday September 21. Per Fierce, the offering was upsized from 21.7 million shares, and proceeds fund ipsoprubart’s Phase 2/3 program in secondary hemophagocytic lymphohistiocytosis ($220 million), a Phase 1 in NK/T cell malignancies ($25 million), and ELA822’s Phase 1/2 in T cell mediated immune disorders ($50 million), on top of $97.7 million of June 30 cash. Endpoints counts Electra as the 21st biotech IPO of 2026. Closing at the session low, below issue on day one, is the first stress signal from a window that had been absorbing supply comfortably.

What did the FDA approve for Eli Lilly’s Inluriyo?

The FDA approved Inluriyo (imlunestrant) combined with Verzenio (abemaciclib) for adults with ER positive, HER2 negative, ESR1 mutated advanced or metastatic breast cancer previously treated with endocrine therapy. In EMBER-3, the combination doubled median progression free survival to 11.1 months versus 5.5 months.

The hazard ratio was 0.53 (95% CI 0.35 to 0.80), per Lilly’s release. Serious adverse reactions occurred in 21% of combination patients and fatal reactions in 3.8%. Inluriyo’s monotherapy approval came in September 2025 for the same population; Lilly says the drug now reaches over half of patients starting an oral SERD. The label expansion sharpens the contrast with AstraZeneca’s Etcamah, which won its resistance signal switch approval September 9 and then missed its first line SERENA-4 trial within the week, and with Roche’s giredestrant, per Fierce’s framing of the oral SERD race.

Who bought what: the platform and pipeline ledger extends

Novo acquired three early stage, explicitly non incretin obesity programs from Kallyope on Friday, the fifth pipeline or platform purchase disclosed in five sessions. Financial terms were not disclosed. The lead asset, K-554, is a once weekly peptide described as IND ready.

The deal color comes from LinkedIn posts by Novo research and business development executives and a spokesperson’s confirmation to Fierce that the purchase is new business, not an extension of a prior partnership. It lands in the same week as Novo’s up to $1.4 billion Orbis Medicines macrocycle pact, Roche’s Dualitas bispecific screening deal, SK Biopharmaceuticals’ 1ST Biotherapeutics Parkinson’s license, and Novartis’ $125 million Sironax brain delivery purchase. The other direction also showed itself Friday: Bristol Myers Squibb returned ORM-6151, its $100 million upfront CD33 degrader antibody conjugate licensed from Orum Therapeutics in 2023, after reviewing Phase 1 data in AML and MDS, costing Orum up to $80 million in development milestones, per Fierce reporting on the disclosure. Engines are commanding premiums while single assets keep getting handed back.

What did Europe’s CHMP recommend this month?

The CHMP issued positive opinions for seven new medicines September 18, including Novo’s hemophilia A bispecific Frehemgo and AstraZeneca and Alexion’s Klygefa, the first nanobody for generalized myasthenia gravis, plus eleven label extensions. MaaT Pharma’s Xervyteg received a negative opinion.

The committee also recommended Enhertu for an adjuvant breast cancer indication among the extensions, and cleared two biosimilars and two generics.

What is in China’s new five year biotech plan?

China published a five year plan September 18 targeting a 3.5 trillion yuan pharmaceutical industry by 2030, roughly $522 billion at BioSpace’s conversion, and calling for five domestically developed medicines to reach global blockbuster status in that window.

The plan, reported by Xinhua and Caixin, frames the goal as cementing China’s place at the forefront of biomedical innovation. It arrives with US Section 232 pharmaceutical tariff decisions due September 29 and follows a year in which Chinese originated assets have anchored a growing share of global licensing deals.

Where do Grail’s briefing documents stand before Tuesday’s panel?

As of Sunday evening September 20, the FDA meeting page for Tuesday’s Molecular and Clinical Genetics Panel carries no briefing documents, no executive summary, and no panel questions, only two conflict waiver PDFs. The first ever premarket approval panel for a multi cancer early detection test convenes in under 48 hours without public materials.

The September 23 meeting, docket FDA-2026-N-8004, will review Grail’s Galleri, a next generation sequencing test detecting cancer specific methylation patterns. Briefing documents typically post about two business days before a panel; the expectation had been around September 21, so a Monday posting would still be in the historical window, but a panel week opening with nothing public is worth stating plainly. GRAL closed Friday at $80.77, up 1.0%.

How did the rest of the tape close the week?

Outside Xenon, Friday was an orderly session with the pain concentrated in names that had run. Sionna fell 17.0% with no disclosure found; Ionis resumed its slide at 4.9% down; Amylyx gave back 4.5%.

The weekend itself was quiet: sweeps of company wires, the FDA newsroom, and the major trade fronts through Sunday evening found no Saturday or Sunday disclosures. Large caps were little changed: LLY $1,152.93, NVO $43.24 (+0.1%), NVS $140.37 (−0.4%), AZN $166.08, GSK ADR $50.22 (−1.6%), VRTX $508.34 (−1.6%), BMY $63.06 (+0.4%), MRK $146.87 (−0.2%), GILD $150.11 (−0.5%).

What is on the calendar this week and beyond?

Four dated disclosures land inside six business days: Grail’s panel Tuesday September 23, AbbVie’s full CERVINO etentamig data September 25, Section 232 pharmaceutical tariffs September 29, and the GENEROUS Medicaid MFN opt in deadline September 30. GSK’s stated window for its mRNA flu Phase 3 start also closes with the month, and EASD opens September 28 in Milan, where Novo has pre announced 44 abstracts including real world Wegovy pill data and its amylin pipeline. Farther out: uniQure’s AMT-130 acceptance decision around early November, Summit’s ivonescimab decision November 14, Capricor’s deramiocel PDUFA November 22, Vertex’s povetacicept PDUFA November 30, and the anito-cel action date December 23.

Frequently asked questions

Why did Xenon stock drop on September 18, 2026?

Xenon paused new enrollment in its Phase 3 depression trials X-NOVA2 and X-CEED after an analysis of neuropsychiatric adverse events, disclosed in the same September 17 release as its azetukalner NDA submission for focal seizures. XENE fell 30.7% to $39.75 in the first session after the news.

Is azetukalner’s epilepsy program affected by the depression trial pause?

No. Xenon says the X-TOLE3 and X-ACKT epilepsy studies continue unaffected, and the NDA for focal seizures was submitted on the strength of X-TOLE and X-TOLE2. BioSpace reported an anticipated FDA decision in September 2027.

When will Xenon report X-NOVA2 topline data?

First quarter of 2027, earlier than prior first half guidance, because enrollment will close near 360 patients instead of the planned 450.

How much does Fayuvi cost?

Ultragenyx set the US wholesale acquisition cost at $3.95 million per patient, stated by an executive on the company’s approval call and reported by Reuters, Endpoints, and BioSpace citing Jefferies. No pricing document has been published; BioSpace places it second only to Lenmeldy’s $4.25 million among gene therapies.

How did Ultragenyx stock react to the Fayuvi approval?

RARE closed essentially flat at $14.51 in Friday’s first full reaction session, after rising 12.6% Thursday before the evening release crossed. The approval, price, and launch details were fully disclosed by Friday’s open.

What price did Electra Therapeutics IPO at, and where did it close?

Electra priced 23,333,334 shares at $15.00 for approximately $350.0 million gross, upsized from 21.7 million shares, and closed its first session at $13.25, 11.7% below the offer. The deal closes September 21.

What did the FDA approve for Inluriyo in September 2026?

Inluriyo (imlunestrant) in combination with Verzenio (abemaciclib) for adults with ER positive, HER2 negative, ESR1 mutated advanced or metastatic breast cancer after endocrine therapy, based on EMBER-3’s 11.1 versus 5.5 month median PFS and a 0.53 hazard ratio.

What obesity assets did Novo buy from Kallyope?

Three early stage non incretin programs: K-554, a once weekly IND ready peptide; a follow on small molecule; and a small molecule receptor agonist. Terms were not disclosed.

What did Bristol Myers Squibb return to Orum Therapeutics?

ORM-6151, also called BMS-986497, a CD33 targeting degrader antibody conjugate for AML and MDS licensed for $100 million upfront in 2023, dropped after a Phase 1 data review, per Fierce. Orum loses up to $80 million in development milestones.

What did the CHMP recommend at its September 2026 meeting?

Seven new medicines including Novo’s Frehemgo for hemophilia A and AstraZeneca and Alexion’s Klygefa for generalized myasthenia gravis, plus eleven label extensions including adjuvant Enhertu, two biosimilars, and two generics. MaaT Pharma’s Xervyteg was rejected.

What does China’s new five year pharma plan target?

A 3.5 trillion yuan pharmaceutical industry by 2030, about $522 billion per BioSpace’s conversion, with five domestic medicines reaching global blockbuster status.

When is the Grail Galleri FDA advisory committee meeting?

Tuesday September 23, 2026, the first premarket approval panel for a multi cancer early detection test, under docket FDA-2026-N-8004. As of Sunday evening September 20, no briefing documents had been posted to the meeting page.

When does Boston Scientific quantify its cyberattack impact?

The company has pointed detailed financial metrics to its October 28 third quarter call, after saying operations were fully restored and that quarterly and full year guidance would likely be missed.

What are the biggest FDA decisions left in 2026?

Summit’s ivonescimab and BioXcel’s Igalmi sNDA on November 14, Capricor’s deramiocel November 22, Vertex’s povetacicept November 30, Mineralys’ lorundrostat in December, Hansa’s imlifidase December 19, and the anito-cel action date December 23.

Sources

Primary sources: Xenon Pharmaceuticals NDA and psychiatry update release (GlobeNewswire, September 17, 2026, 4:01 pm ET); Electra Therapeutics IPO pricing release (September 17, 2026); Eli Lilly Inluriyo approval release (investor.lilly.com, September 18, 2026); FDA press announcement on the Fayuvi approval (September 17, 2026); FDA advisory committee meeting page for the September 23, 2026 Molecular and Clinical Genetics Panel (checked September 20, 2026); Xinhua and Caixin on China’s biomedical five year plan (September 18, 2026); Nasdaq exchange closes for September 18, 2026.

Trade press: BioSpace (Xenon hold analysis; Fayuvi pricing, September 18); Fierce Biotech (Novo/Kallyope, BMS/Orum, Electra, September 18); Fierce Pharma (Inluriyo, CHMP roundup, September 18); Endpoints News (Fayuvi price, Electra IPO count, weekly recap, September 18 to 19); Reuters wire (Ultragenyx call statement, September 17); STAT (Roche Boston research center, September 18).

Related coverage

• The FDA approved Fayuvi two days early as Kerendia won a 30 year first and Novo signed its macrocycle pact
• Vera’s Trutakna cut kidney disease progression risk 76% over two years
• Scholar Rock’s Isembyld won FDA approval 19 days early
• Amgen named no readout dates at Morgan Stanley
• The FDA paused Biohaven’s pivotal epilepsy enrollment two weeks after its up to $795M SK deal